Bayer anticipates immediate pharma bounce back after 2024 blip

11 March 2021

German company Bayer (BAYN: DE) is confident that it can bounce back from a decline in the Pharmaceuticals division’s sales in 2024 due to the patent expirations for established blockbusters Xarelto (rivaroxaban) and Eylea (aflibercept).

Making the forecasts at its Capital Markets Day for 2021 on Wednesday, Bayer predicts the Pharmaceuticals Division will post robust annual sales growth of 3% to 5% through 2023.

But, in 2024, Bayer anticipates a low- to mid-single digit percentage decline in this division’s sales due to the patent expiries.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK